CRSP icon

CRISPR Therapeutics
CRSP

Overview Fund Activity

434 hedge funds and large institutions have $3.7B invested in CRISPR Therapeutics in 2022 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 129 increasing their positions, 115 reducing their positions, and 50 closing their positions.

Holders
434
Holders Change
+1
Holders Change %
+0.23%
% of All Funds
7.5%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.14%
New
58
Increased
129
Reduced
115
Closed
50
Calls
$223M
Puts
$213M
Net Calls
+$10.5M
Net Calls Change
+$83K

Top Buyers

1
Macquarie Group
1
Macquarie Group
Australia
$54.8M
2
Capital International Investors
2
Capital International Investors
California
$349M
3
Fidelity Investments
3
Fidelity Investments
Massachusetts
$140M
4
Baillie Gifford & Co
4
Baillie Gifford & Co
United Kingdom
$18.9M
5
Charles Schwab
5
Charles Schwab
California
$40.7M

Top Sellers

1
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$77.6M
2
AIM
2
ARK Investment Management
Florida
$538M
3
PAMS
3
Pictet Asset Management (Switzerland)
Switzerland
$2.37M
4
Sumitomo Mitsui Trust Group
4
Sumitomo Mitsui Trust Group
Japan
$279M
5
NAMA
5
Nikko Asset Management Americas
New York
$277M
Name Holding Trade Value Shares
Change 		Shares
Change %
CI
476
CX Institutional
Indiana
– -$1K -10 Closed
BIA
477
Bell Investment Advisors
California
– -$1K -9 Closed
GCS
478
Gordian Capital (Singapore)
Singapore
– -$1K -1 Closed
Man Group
479
Man Group
United Kingdom
– -$3.39M – –
16 17 18 19
20